Dr. Nishi Suryavanshi Receives Award from ACTG Network

Date: 01/07/2022

Congratulations, Nishi Suryavanshi, recipient of ACTG’s Tuberculosis Transformative Science Group Special Contributions Award.

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....